Loading organizations...
§ Private Profile · Houston, TX, USA
Biotech company developing dual-payload antibody-drug conjugates (ADCs) for oncology, designed to overcome tumor resistance.
CrossBridge Bio is a Houston, Texas-based biotechnology company developing next-generation dual-payload antibody-drug conjugates for targeted oncology treatments. The enterprise utilizes proprietary branched tripeptide linker technology to precisely deliver synergistic drug combinations within single molecules, designed to overcome tumor resistance and address cancer heterogeneity. To support its research operations, the business has raised $10 million in seed funding from institutional backers including TMC Venture Fund, CE-Ventures, and its parent organization Crescent Enterprises. The company's clinical pipeline features the lead asset CBB-120, a TROP-2 targeted dual-payload therapeutic that recently earned the firm recognition as the top drug developer at the 2025 World ADC Awards. This primary therapeutic candidate is currently advancing through preclinical stages with an investigational new drug filing scheduled for 2026. CrossBridge Bio was founded in 2023 by Michael Torres and Kyoji Tsuchikama.
CrossBridge Bio has raised $25.0M across 2 funding rounds.
CrossBridge Bio has raised $25.0M in total across 2 funding rounds.
CrossBridge Bio has raised $25.0M across 2 funding rounds. Most recently, it raised $15.0M Grant in November 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 20, 2025 | $15M Grant | Cancer Prevention And Research Institute OF Texas | — | Announced |
| Nov 4, 2024 | $10M Seed | Crescent Enterprises, William Mckeon | Alexandria Venture Investments, Linden Lake Labs, Portal Innovations | Announced |
CrossBridge Bio has raised $25.0M in total across 2 funding rounds.
CrossBridge Bio's investors include Cancer Prevention and Research Institute of Texas, Crescent Enterprises, William McKeon, Alexandria Venture Investments, Linden Lake Labs, Portal Innovations.